Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P21817 (
RyR1
)
1,154
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Triadin
in the junctional sarcoplasmic reticulum (SR) of skeletal muscle cells has been suggested to interact with
ryanodine receptor 1
(
RYR1
) via its KEKE motifs. Recently, we showed that amino acid residues D4878, D4907, and E4908 in
RYR1
are critical for triadin-binding in vitro [J.M. Lee, S.H. Rho, D.W. Shin, C. Cho, W.J. Park, S.H. Eom, J. Ma, D.H. Kim, Negatively charged amino acids within the intraluminal loop of ryanodine receptor are involved in the interaction with triadin, J. Biol. Chem. 279 (2004) 6994-7000]. In order to test whether a disruption of the triadin-binding site(s) in
RYR1
affects SR Ca(2+) release, alanine-substituted single (D4878A, D4907A, and E4908A) and triple (
RYR1
-TM) mutants of D4878, D4907, and E4908 were expressed in
RYR1
-null myotubes. Co-immunoprecipitation experiments showed a 50-60% decrease of triadin brought down in the D4907A and
RYR1
-TM complexes compared to the triadin-wtRYR1 complex. Ca(2+) imaging experiments using Fluo-4-AM showed atypical caffeine responses in myotubes expressing D4907A and
RYR1
-TM characterized by either a lack of or slower activation and faster inactivation of Ca(2+) transients. The results suggest that disruption of interaction between triadin and
RYR1
impairs
RYR1
function and SR Ca(2+) release.
...
PMID:Occurrence of atypical Ca2+ transients in triadin-binding deficient-RYR1 mutants. 1709 84
Ca(2+) release from intracellular stores is controlled by complex interactions between multiple proteins.
Triadin
is a transmembrane glycoprotein of the junctional sarcoplasmic reticulum of striated muscle that interacts with both calsequestrin and the type 1 ryanodine receptor (
RyR1
) to communicate changes in luminal Ca(2+) to the release machinery. However, the potential impact of the triadin association with
RyR1
in skeletal muscle excitation-contraction coupling remains elusive. Here we show that triadin binding to
RyR1
is critically important for rapid Ca(2+) release during excitation-contraction coupling. To assess the functional impact of the triadin-
RyR1
interaction, we expressed
RyR1
mutants in which one or more of three negatively charged residues (D4878, D4907, and E4908) in the terminal
RyR1
intraluminal loop were mutated to alanines in
RyR1
-null (dyspedic) myotubes. Coimmunoprecipitation revealed that triadin, but not junctin, binding to
RyR1
was abolished in the triple (D4878A/D4907A/E4908A) mutant and one of the double (D4907A/E4908A) mutants, partially reduced in the D4878A/D4907A double mutant, but not affected by either individual (D4878A, D4907A, E4908A) mutations or the D4878A/E4908A double mutation. Functional studies revealed that the rate of voltage- and ligand-gated SR Ca(2+) release were reduced in proportion to the degree of interruption in triadin binding. Ryanodine binding, single channel recording, and calcium release experiments conducted on WT and triple mutant channels in the absence of triadin demonstrated that the luminal loop mutations do not directly alter
RyR1
function. These findings demonstrate that junctin and triadin bind to different sites on
RyR1
and that triadin plays an important role in ensuring rapid Ca(2+) release during excitation-contraction coupling in skeletal muscle.
...
PMID:Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling. 1784 66
Triadin
and junctin are integral sarcoplasmic reticulum membrane proteins that form a macromolecular complex with the
skeletal muscle ryanodine receptor
(
RyR1
) but their roles in skeletal muscle calcium homeostasis remain incompletely understood. Here we report that delivery of siRNAs specific for triadin or junctin into C2C12 skeletal myoblasts reduced the expression of triadin and junctin in 8-day-old myotubes by 80 and 100%, respectively. Knocking down either triadin or junctin in these cells reduced Ca2+ release induced by depolarization (10mM KCl) by 20-25%. Unlike triadin knockdown myotubes, junctin knockdown and junctin/triadin double knockdown myotubes also had reduced Ca2+ release induced by 400 microM 4-chloro-m-cresol, 10mM caffeine, 400 microM UTP, or 1 microM thapsigargin. Thus, knocking down junctin compromised the Ca2+ stores in the sarcoplasmic reticulum of these cells. Our subsequent studies showed that in junctin knockdown myotubes at least two sarcoplasmic reticulum proteins (
RyR1
and skeletal muscle calsequestrin) were down-regulated while these proteins' mRNA expression was not affected. The results suggest that triadin has a role in facilitating KCl depolarization-induced Ca2+ release in contrast to junctin which has a role in maintaining sarcoplasmic reticulum Ca2+ store size in C2C12 myotubes.
...
PMID:Altered stored calcium release in skeletal myotubes deficient of triadin and junctin. 1862 Jul 51
Calcium is a crucial element for striated muscle function. As such, myoplasmic free Ca(2+) concentration is delicately regulated through the concerted action of multiple Ca(2+) pathways that relay excitation of the plasma membrane to the intracellular contractile machinery. In skeletal muscle, one of these major Ca(2+) pathways is Ca(2+) release from intracellular Ca(2+) stores through type-1 ryanodine receptor/Ca(2+) release channels (
RyR1
), which positions
RyR1
in a strategic cross point to regulate Ca(2+) homeostasis. This major Ca(2+) traffic point appears to be highly sensitive to the intracellular environment, which senses through a plethora of chemical and protein-protein interactions. Among these modulators, perhaps one of the most elusive is
Triadin
, a muscle-specific protein that is involved in many crucial aspect of muscle function. This family of proteins mediates complex interactions with various Ca(2+) modulators and seems poised to be a relevant modulator of Ca(2+) signaling in cardiac and skeletal muscles. The purpose of this review is to examine the most recent evidence and current understanding of the role of
Triadin
in muscle function, in general, with particular emphasis on its contribution to Ca(2+) homeostasis.
...
PMID:On the footsteps of Triadin and its role in skeletal muscle. 2190 59
Triadin
isoforms, splice variants of one gene, maintain healthy Ca
2+
homeostasis in skeletal muscle by subserving several functions including an influence on Ca
2+
release through the ligand-gated ryanodine receptor (
RyR1
) ion channels. The predominant triadin isoform in skeletal muscle, Trisk 95, activates
RyR1
in vitro via binding to previously unidentified amino acids between residues 200 and 232. Here, we identify three amino acids that influence Trisk 95 binding to
RyR1
and ion channel activation, using peptides encompassing residues 200-232. Selective alanine substitutions show that K
218
, K
220
, and K
224
together facilitate normal Trisk 95 binding to
RyR1
and channel activation. Neither
RyR1
binding nor activation are altered by alanine substitution of K
220
alone or of K
218
and K
224
. Therefore K
218
, K
220
, and K
224
contribute to a robust binding and activation site that is disrupted only when the charge on all three residues is neutralized. We suggest that charged pair interactions between acidic
RyR1
residues D
4878
, D
4907
, and E
4908
and Trisk 95 residues K
218
, K
220
, and K
224
facilitate Trisk 95 binding to
RyR1
and channel activation. Since K
218
, K
220
, and K
224
are also required for CSQ binding to RyRs (Kobayashi et al. 17, J Biol Chem 275, 17639-17646), the results suggest that Trisk 95 may not simultaneously bind to
RyR1
and CSQ, contrary to the widely held belief that triadin monomers form a quaternary complex with junctin, CSQ and
RyR1
. Therefore, the in vivo role of triadin monomers in modulating
RyR1
activity is likely unrelated to CSQ.
...
PMID:Three residues in the luminal domain of triadin impact on Trisk 95 activation of skeletal muscle ryanodine receptors. 2759 38